Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor

被引：7
|
作者：
Kotecki, N. [1 ]
Champiat, S. [2 ]
Delord, J-P. [3 ]
Vinceneux, A. [4 ]
Jungels, C. [1 ]
Marabelle, A. [2 ]
Korakis, I. [3 ]
Wojciekowski, S. [5 ]
Block, E. [6 ]
Clarke, N. [7 ]
Fromond, C. [8 ]
Poirier, N. [9 ]
Costantini, D. [10 ]
Vasseur, B. [11 ]
Cassier, P. A. [4 ]
机构：
[1] Inst Jules Bordet, Med Oncol, Brussels, Belgium
[2] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France
[3] Inst Claudius Regaud, Dept Med Oncol, IUCT Oncopole, Toulouse, France
[4] Ctr Leon Berard, Med Oncol, Lyon, France
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Dept Stat, Biberach, Germany
[6] Boehringer Ingelheim Pharmaceut Inc, Clin Dev, Ridgefield, CT USA
[7] Boehringer Ingelheim Pharma GmBH & Co KG, Translat Med & Clin Pharmacol, Ingelheim, Germany
[8] OSE Immunotherapeut, Preclin Dev & Translat Med, Paris, France
[9] OSE Immunotherapeut, Res Dept, Nantes, France
[10] OSE Immunotherapeut, Early Dev, Paris, France
[11] OSE Immunotherapeut, Immunooncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
983P
引用
收藏
页码：S841 / S842
页数：2
相关论文
共 50 条
  • [21] Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies
    Seitz, L. C.
    Rieger, A.
    Berry, W.
    Ashok, D.
    Direnzo, D.
    Jin, L.
    Lee, S. J.
    Park, A.
    Piovesan, D.
    Tan, J. B. L.
    Walters, M. J.
    Karakunnel, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
    Mross, Klaus
    Frost, Annette
    Steinbild, Simone
    Hedbom, Susanne
    Rentschler, Jochen
    Kaiser, Rolf
    Rouyrre, Nicolas
    Trommeshauser, Dirk
    Hoesl, Cornelia E.
    Munzert, Gerd
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5511 - 5517
  • [23] A phase I single dose escalation study of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors.
    Mross, K
    Steinbild, S
    Frost, A
    Hedborn, S
    Rentschler, J
    Kaiser, R
    Trommeshauser, D
    Stehle, G
    Munzert, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9032S - 9032S
  • [24] A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors
    Laurie, Scott Andrew
    Jonker, Derek J.
    Edenfield, William Jeffery
    Stephenson, Joe
    Keller, Deborah
    Hitron, Matthew
    Li, Wei
    Li, Youzhi
    Gada, Keyur
    Gao, Yuan
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors
    Desai, Jayesh
    Markman, Ben
    Sandhu, Shahneen Kaur
    Gan, Hui Kong
    Friedlander, Michael
    Tran, Ben
    Meniawy, Tarek
    Boolell, Vishal
    Colyer, Duncan
    Norris, Christie
    Ameratunga, Malaka
    Yang, Jason
    Li, Kang
    Wang, Lai
    Luo, Lusong
    Qin, Zhen
    Millward, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Kuboki, Yasutoshi
    Harano, Kenichi
    Koyama, Takafumi
    Kondo, Shunsuke
    Hagiwara, Akiko
    Suzuki, Noriko
    Fujikawa, Ei
    Toyoizumi, Kiichiro
    Mukai, Mayumi
    Doi, Toshihiko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 376 - 385
  • [27] Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab inpatients with advanced solid tumors: results from two phase I trials
    Liu, F. -R.
    Wei, X. -L.
    Feng, W. -N.
    Zhao, H. -Y.
    Zhang, Y.
    Wang, Z. -Q.
    Zhang, D. -S.
    Wang, F. -H.
    Yang, S.
    Pan, W.
    Men, L.
    Wang, H.
    Liang, E.
    Wang, C.
    Yang, D.
    Zhai, Y.
    Qiu, M. -Z.
    Xu, R. -H.
    ESMO OPEN, 2024, 9 (08)
  • [28] METEOR-1: A phase I study GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
    Siu, L. L.
    Rasco, D. W.
    Vinay, S. Postel
    Romano, P. Martin
    Menis, J.
    Opdam, F. L.
    Heinhuis, K. M.
    Egger, J. L.
    Gorman, S. A.
    Parasrampuria, R.
    Wang, K.
    Kremer, B. E.
    Gounder, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 159 - 159
  • [29] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
    Kyriakos P. Papadopoulos
    Nehal Lakhani
    Gerald S. Falchook
    Gosia Riley
    Johan Baeck
    Karen S. Brown
    Gilad Gordon
    Lidya Le
    Judy S. Wang
    Cancer Immunology, Immunotherapy, 2021, 70 : 763 - 772
  • [30] Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
    Papadopoulos, Kyriakos P.
    Lakhani, Nehal
    Falchook, Gerald S.
    Riley, Gosia
    Baeck, Johan
    Brown, Karen S.
    Gordon, Gilad
    Le, Lidya
    Wang, Judy S.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (03) : 763 - 772
12345